Iron

Iron is one of the most-studied minerals in supplementation research, and the literature divides cleanly into two questions with very different evidence shapes: treating iron deficiency in at-risk populations (where evidence is overwhelmingly positive and clinical consensus is clear) and routine supplementation in healthy adults with adequate intake (where evidence is limited and supplementation is not generally recommended). Supplemental forms vary substantially in bioavailability and gastrointestinal tolerability: ferrous sulfate is the historical standard and most-studied form; ferrous gluconate and fumarate are other common salts, and chelated forms such as iron bisglycinate are studied mainly for tolerability.

The outcome dimensions covered most heavily are pregnancy (the most-studied supplementation context), infant and toddler iron requirements (where breast milk alone becomes insufficient around 6 months of age), iron-deficiency anemia treatment in adolescent girls and menstruating women, supplementation in vegetarian and vegan diets (where non-heme dietary iron is less bioavailable), and supplementation in people with celiac disease, inflammatory bowel disease, or post-gastric-bypass (where absorption is impaired). Smaller research streams cover athletic performance (especially endurance, in iron-deficient or low-ferritin athletes) and cognitive function in iron-deficient populations.

Demographically, pregnant women dominate the largest body of supplementation evidence; pediatric populations dominate the prevention literature; older adults feature in the absorption-impairment literature. Dosing strategy is an active research area: the regulatory hormone hepcidin rises in response to daily oral iron, which is the mechanistic basis for ongoing research into alternate-day dosing strategies. Form choice (ferrous sulfate vs. iron bisglycinate vs. others) is studied mainly for gastrointestinal tolerability, and head-to-head comparisons remain limited outside pregnancy.

Oral iron is widely used in people with iron deficiency or low iron status, but side effects are common. The most-common adverse effects of supplementation are gastrointestinal: constipation, nausea, abdominal discomfort, and dark stools, which improve with form selection (chelated forms such as iron bisglycinate might be better-tolerated) or alternate-day dosing. The tolerable upper limit for adults is 45 mg/day. Acute iron toxicity is a serious safety concern: iron is among the leading causes of pediatric accidental poisoning deaths, and household iron supplements should be stored well out of reach of children. Long-term iron overload (hemochromatosis, repeated transfusions, certain genetic conditions) can cause organ damage, which is why routine supplementation in people with adequate iron status is not recommended. Iron reduces absorption of levothyroxine, levodopa, quinolones, tetracyclines, and bisphosphonates; proton pump inhibitors in turn reduce iron absorption. People with hemochromatosis, hereditary iron overload, or recent gastric surgery should not supplement without medical supervision.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.